Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

HLH-JAK, the first OPEN-label, phase II study evaluating ANTI-JAK1 itacitinib, for NON severe HLH in adults.

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMarc Michel

Discussion

Loading...

Member takes

Overview

Phase II trial achieved 71% response rate in 35 adults with HLH, suggesting Itacitinib's potential as a treatment.

Key Points

  • Itacitinib achieves a 71% response rate at day 15 for non-severe HLH patients, with significant early responses observed.
  • The number of patients showing complete or partial response meets the pre-specified efficacy threshold for treatment.
  • Assessment of treatment used a Simon optimal two-stage design and included seven clinical and biological parameters.
  • These preliminary results indicate Itacitinib is well tolerated, with only mild adverse effects reported, warranting further clinical trials.

Cite This Study

Marc Michel (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd37https://doi.org/10.1182/blood-2025-190
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025
  2. 2HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis2026
  3. 3Ruxolitinib in malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH): A systematic literature review2025
  4. 4An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation2025
  5. 5Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis2025